 Connection
M Cave to Antibiotics, Antitubercular
This is a "connection" page, showing publications M Cave has written about Antibiotics, Antitubercular.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.075 |
|
|
|
-
Johnson JL, Okwera A, Nsubuga P, Nakibali JG, Whalen CC, Hom D, Cave MD, Yang ZH, Mugerwa RD, Ellner JJ. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis. 2000 Nov; 4(11):1032-40.
Score: 0.047
-
Hazb?n MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, Garc?a-Garc?a L, Le?n CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce de Le?n A, Alland D. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006 Aug; 50(8):2640-9.
Score: 0.017
-
Hellyer TJ, DesJardin LE, Hehman GL, Cave MD, Eisenach KD. Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis. J Clin Microbiol. 1999 Feb; 37(2):290-5.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|